NCT04532281View on ClinicalTrials.gov

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2026

Conditions

Acute Lymphoblastic LeukemiaNon-Hodgkin Lymphoma of Soft Tissue

Interventions

DRUG

Murine CD19 CAR-T cells

Each subject receive murine CD19 CAR T-cells by intravenous infusion

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER

NCT04532281 - A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies | Biotech Hunter | Biotech Hunter